Legend Biotech (LEGN) Corporate presentation summary

Company overview and strategic positioning

• Employs 2,800 people, with over 450 focused on R&D and 10 pipeline programs in hematologic malignancies, solid tumors, and autoimmune diseases.

• Maintains end-to-end capabilities and partnerships with Johnson & Johnson and Novartis.

• Holds $1.0B in cash, cash equivalents, and time deposits as of September 30, 2025.

CARVYKTI® performance and clinical impact

• CARVYKTI® is the first and only CAR-T therapy to show superior overall survival (OS) versus standard of care (SOC) in multiple myeloma, with over 9,000 patients treated globally.

• Achieved a 45% reduction in risk of death compared to SOC in lenalidomide-refractory multiple myeloma, with a 30-month OS of 76.4% versus 63.8% for SOC.

• Demonstrated ≥5-year remission and survival in a third of patients in the CARTITUDE-1 study, with a median OS of 60.7 months.

• Recognized by the International Myeloma Working Group as preferred before bispecific T-cell engagers.

Market leadership and commercial growth

• CARVYKTI® achieved record-breaking quarterly sales, becoming the highest-selling CAR-T therapy in a single quarter, with a 111% CAGR since launch.

• Net trade sales grew 84% year-over-year globally in Q2 2025, with significant uptake in both the U.S. and international markets.

• Expanded U.S. treatment sites from 44 in 2022 to 131 in 2025, including community hospitals and practices.